The short version
Membership-model peptide platforms charge a recurring fee — monthly, quarterly, or annual — for ongoing access to clinicians, labs, and the option to add prescriptions. Per-protocol platforms charge for the prescription and the clinical evaluation it requires, with no recurring access fee. Both can be staffed by U.S.-licensed providers. Both can use 503A compounding pharmacies. The difference is what you're paying for between prescriptions.
If your protocol is one peptide for a defined goal over a defined window, you're probably paying for membership you don't use. If you want a continuous coaching relationship, the membership is the actual product.
| Topic | Membership model | Per-protocol model |
|---|---|---|
| Recurring fee | Monthly / quarterly / annual | None — pay per protocol |
| Best fit | Want ongoing relationship + labs cadence | Want a specific protocol with provider oversight |
| Peptide cost | Often included or discounted within membership | Charged transparently per prescription |
| Coaching / interpretation | Bundled into membership | Within the focused clinical evaluation |
| Lab cadence | Often quarterly, member-paced | Goal-driven, not calendar-driven |
| Cancel friction | Membership terms vary | None — no recurring commitment |
What the membership model is optimized for
Membership platforms are optimized for the buyer who wants a long-running relationship with their care team — someone who values quarterly bloodwork interpreted by the same coach, gradual protocol iteration, and a single login that holds their full health picture. The recurring fee funds the team's availability between visits. For that buyer, the membership is the product, not a tax on the prescription.
That model has a real audience. People rebuilding from significant lifestyle change, executives who want continuous oversight, anyone whose goal is "stay calibrated over years" rather than "address this specific thing." For that buyer, paying per protocol would feel undersupported.
Membership economics work for the buyer who wants the relationship. Per-protocol works for the buyer who wants the protocol.
Where membership falls short for a different buyer
If you came in with a specific protocol in mind — a peptide for tendon recovery, a six-month sleep-support cycle, a defined recomp window — the membership economics work against you. You're funding ongoing-relationship infrastructure you don't need this year. The peptide itself is often marked up to fit inside the membership envelope, and "free labs" inside a membership cost real money to provide.
The other quiet issue: membership lock-in subtly discourages stopping. If your goal is a six-month cycle and you'd otherwise be done, the recurring fee creates a small incentive to keep going. That's not bad faith on the platform's part — it's just what membership economics look like from the buyer's seat.
What Boswell is built for
Boswell is a per-protocol platform. You pay for the clinical evaluation and the prescription. There's no recurring access fee. If your protocol runs four months, you pay for four months. If you renew, you renew. If you don't, you don't.
That structure fits the buyer who already has a goal in mind and wants the prescription pathway around it. How it works covers the steps. The provider checklist is useful regardless of which model you pick — same questions either way. And if you want a direct comparison with a specific membership-model platform, Boswell vs. Lifeforce and Boswell vs. Marek Health go further.
Questions worth asking before either
- What am I actually paying the recurring fee for between prescriptions?
- If my protocol is six months, what does the total cost look like under each model?
- How are labs priced — bundled, marked-up, or at cost?
- What's the cancellation process and is there a minimum term?
- Is the prescriber a U.S.-licensed physician and is the pharmacy a 503A facility?
Sources